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Abstract
Background: Insulin resistance is a risk factor for type 2 diabetes and cardiovascular disease progression. Current diagnostic
tests, such as glycemic indicators, have limitations in the early detection of insulin resistant individuals. We searched for
novel biomarkers identifying these at-risk subjects.
Methods: Using mass spectrometry, non-targeted biochemical profiling was conducted in a cohort of 399 nondiabetic
subjects representing a broad spectrum of insulin sensitivity and glucose tolerance (based on the hyperinsulinemic
euglycemic clamp and oral glucose tolerance testing, respectively).
Results: Random forest statistical analysis selected a-hydroxybutyrate (a–HB) as the top-ranked biochemical for separating
insulin resistant (lower third of the clamp-derived MFFM=33 [12] mmol?min
21?kgFFM
21, median [interquartile range], n=140)
from insulin sensitive subjects (MFFM=66 [23] mmol?min
21?kgFFM
21) with a 76% accuracy. By targeted isotope dilution assay,
plasma a–HB concentrations were reciprocally related to MFFM; and by partition analysis, an a–HB value of 5 mg/ml was
found to best separate insulin resistant from insulin sensitive subjects. a–HB also separated subjects with normal glucose
tolerance from those with impaired fasting glycemia or impaired glucose tolerance independently of, and in an additive
fashion to, insulin resistance. These associations were also independent of sex, age and BMI. Other metabolites from this
global analysis that significantly correlated to insulin sensitivity included certain organic acid, amino acid, lysophospholipid,
acylcarnitine and fatty acid species. Several metabolites are intermediates related to a-HB metabolism and biosynthesis.
Conclusions: a–hydroxybutyrate is an early marker for both insulin resistance and impaired glucose regulation. The
underlying biochemical mechanisms may involve increased lipid oxidation and oxidative stress.
Citation: Gall WE, Beebe K, Lawton KA, Adam K-P, Mitchell MW, et al. (2010) a-Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose
Intolerance in a Nondiabetic Population. PLoS ONE 5(5): e10883. doi:10.1371/journal.pone.0010883
Editor: Massimo Federici, University of Tor Vergata, Italy
Received February 25, 2010; Accepted April 14, 2010; Published May 28, 2010
Copyright:  2010 Gall et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: EGIR-RISC funding support came from Merck Serono and Astra Zeneca. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript. Metabolon, Inc. funded the retrospective analysis herein.
Competing Interests: W. Gall, K. Beebe, K. Lawton, K-P. Adam, M. Mitchell, P. Nakhle, John Ryals, and Mike Milburn are employees of Metabolon, Inc., a private
company. M. Nannipieri, S. Camastra, A. Natali, and E. Ferrannini are faculty of University of Pisa School of Medicine.
* E-mail: wgall@metabolon.com
¤ A complete list of RISC Study Group investigators can be found in supplementary appendix (Appendix S1).
Introduction
Insulin resistance (IR) has been established as a precursor of
type 2 diabetes (T2D) [1,2,3,4,5,6] and cardiovascular disease
[7,8,9,10,11]. IR and compensatory hyperinsulinemia are com-
monly found in a variety of conditions, including obesity. When
coupled with b-cell dysfunction, IR is a major pathophysiological
determinant of dysglycemia (impaired fasting glycemia, IFG, and
impaired glucose tolerance, IGT) and T2D [12,13]. Conditions of
high cardiovascular (CVD) risk such as hypertension, dyslipide-
mia, and atherosclerosis have also been associated with IR
[12,13,14,15]. However, our current understanding of these
associations is incomplete.
Traditional clinical tests do not measure IR directly and, as a
result, a variety of methods have been developed: the gold standard
hyperinsulinemic euglycemic clamp (HI clamp); insulin tolerance
test; steady state plasma glucose (SSPG) following fixed somatostat-
in/glucose/insulin infusions; and modeling analysis of the oral
glucose tolerance test (OGTT) or frequently sampled intravenous
glucose tolerance test (FSIVGTT) [16]. However, such procedures
are mostly confined to clinical research settings due to cost and time
constraints. Fasting insulin and derived indices (HOMA, QUICKI)
have been widely used [17], but lack of insulin measurement
standardization strongly limits their accuracy and has prevented
adoption in routine clinical practice. The identification of novel
markers for detection of IR subjects remains an unmet need.
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identifying individuals at risk of progression to T2D and CVD,
whereby enabling implementation of effective strategies for disease
prevention and patient monitoring.
The RISC study (Relationship of Insulin Sensitivity to Cardio-
vascular Risk), comprising a nondiabetic cohort, was initiated to
address how IR may contribute to T2D and CVD progression. We
report here on a global biochemical profiling technology developed
for the discovery of new biochemical biomarkers. This technology
has been successfully applied to identify biochemicals associated
with disease, toxicity and aging [18,19,20]. Here it was applied to
identify biochemicals associated with IR and dysglycemia in 399
subjects,a subset oftheRISCcohort,inwhichinsulin sensitivitywas
measured directly by the HI clamp. We found that a-hydroxybu-
tyrate (a–HB) is the most significant metabolite associated with
insulin sensitivity and, interestingly, as an early marker for
dysglycemia. The biochemical pathway for a–HB and its potential
involvement in IR and dysglycemia are briefly discussed. Monitor-
ing changes in the concentration of a–HB in fasting human plasma
may provide novel insights on how early stages of IR evolve into
T2D or CVD.
Results
Biochemical Profiling Analysis
Fasting plasma samples from the RISC cohort were analyzed
in a non-targeted fashion on three separate mass spectrometry
platforms, UHPLC-MS/MS (+/- ESI) and GC-MS (+EI), with
485 biochemicals measured, as illustrated in Figure 1A. Each
participant’s insulin sensitivity was measured using the hyperinsu-
linemic euglycemic (HI) clamp; the distribution of MFFM (MFFM=
insulin-mediated glucose disposal rate, mmol?min
21?kgFFM
21)
in the 399 RISC subjects analyzed is shown in Figure 1B.
Taking a commonly used classification approach [11,21,22,23],
the bottom tertile of insulin sensitivity of the entire EGIR-RISC
cohort(n=1293)(i.e.,M FFM#45 mmol?min
21?kgFFM
21)wasdefined
as IR. By this criterion, MFFM was 33 [12] mmol?min
21?kgFFM
21,
median [interquartile range], in the IR group (n=140) and 66 [23]
mmol?min
21?kgFFM
21 in the more insulin sensitive (IS) subjects. The
demographic and metabolic characteristics of the 399 subjects under
analysis are described in Table 1.
a–HB is inversely associated with insulin sensitivity
To assess the ability to classify subjects as IS or IR, Random
Forest (RF) analysis was performed. As shown in Figure 2,t h e
organic acid, a–hydroxybutyrate (a–HB) was the top-ranked
metabolite in the resulting importance plot, which ranks the
classifiers based upon contribution of each to the separation of
the subjects into classes. In this analysis the subjects were
classified as either IS or IR with approximately 76% accuracy
(inset). This result did not change when normalizing the M value
for kg of body weight rather than kg of fat-free mass (data not
shown).
Univariate correlation analysis of the data from the biochemical
profiling screen also ranked a–HB as the metabolite with the
highest correlation to the glucose disposal rate (r=20.45, p-value
1.40E-21, Table 2). a–HB negatively correlated with total glucose
disposal for both MFFM (fat free mass, mmol?min
21?kgFFM
21) and
MWBM (whole body mass, mg?min
21?kg
21, data not shown).
Summarized in Table 2 are additional candidate biomarkers
correlative to insulin sensitivity as measured by the euglycemic
clamp (MFFM) with overlap observed with the initial RF analysis
(Figure 2).
Since the initial analyses were based upon relative quantification
data obtained from the non-targeted biochemical profiling
technology, a targeted assay was developed to provide absolute
quantitative results. As shown in Figure 3, a–HB was consistently
higher (p,0.0001 for both the screening and targeted data) in IR
subjects compared to IS subjects, whether measured by the
screening platform or by the targeted isotopic dilution assay.
a–HB in dysglycemic subjects
Subjects were classified as normoglycemic or dysglycemic based
upon the results of fasting plasma glucose (FPG) and the oral
glucose tolerance test (OGTT) as illustrated in Figure 4. Subjects
with 2-hour glucose levels ,7.8 mmol/l were deemed normal
Figure 1. Global biochemical profiling analysis of a nondiabetic
population. A. Metabolomic analysis schema. Plasma samples
collected from 399 fasting nondiabetic subjects were analyzed on
three separate mass spectrometry platforms. Ultra-high pressure liquid
chromatography-mass spectrometry (UHPLC-MS) was performed in
positive (+ESI) and negative (-ESI) ionization mode and gas chroma-
tography (GC-MS) in positive ionization mode (+EI). An average of ,485
biochemicals was measured in each sample. B. The distribution of
insulin-mediated glucose disposal rates, expressed as MFFM values
(mmol?min
21?kgFFM
21), of 399 subjects selected from the RISC cohort
and comprised of NGT, IGT, and IFG subjects. IR was defined as
M#45 mmol?min
21?kgFFM
21 as measured by clamp, representing the
bottom third of the entire RISC cohort (n=1293). Shaded bars insulin
sensitive (IS); open bars insulin resistant (IR).
doi:10.1371/journal.pone.0010883.g001
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7.8–11.1 mmol/l were deemed as having impaired glucose
tolerance (IGT). Individuals with fasting plasma glucose levels
$5.6 mmol/l were classified as having impaired fasting glucose
(IFG). Thus, based on insulin sensitivity and glucose tolerance
subjects were classified into four categories: NGT insulin sensitive
(NGT-IS); NGT insulin resistant (NGT-IR); IFG; and IGT.
Table 1. Demographic and clinical characteristics of study subjects*.
Group N Parameter Gender Age (years) BMI (kg/m
2) 2-hour glucose (mg/dl) MFFM
NGT-IS 211 Mean 121 f 44 24.1 91 71
Median 90 m 43 23.7 90 68
NGT-IR 45 Mean 20 f 44 25.8 99 35
Median 25 m 45 26.2 99 37
IGT 82 Mean 45 f 46 26.2 156 36
Median 37 m 45 26.1 151 32
IFG 61 Mean 19 f 48 29.3 110 50
Median 42 m 49 28.8 110 45
*MFFM is expressed in mmol?min
21?kgFFM
21; 2-hour plasma glucose levels from the OGTT.
doi:10.1371/journal.pone.0010883.t001
Figure 2. Classification of subjects as insulin sensitive or insulin
resistant. Random Forest statistical analysis of biochemical profiling
(metabolomic) data. The Importance Plot rank of metabolites according
to the contribution of each to the classification of 399 subjects into
insulin sensitive (IS, MFFM.45 mmol?min
21?kgFFM
21, top two-thirds of
subjects, n=261) or insulin resistant (IR, MFFM,45 mmol?min
21?kgFFM
21,
bottom third of subjects, n=138) groups. Metabolites are listed on the
y-axis in order of importance, decreasing in importance from the top to
bottom. Themean decrease in accuracy for each metabolite is plotted on
x-axis. INSET: The Confusion Matrix showing the prediction accuracy
of the separation of the top two-thirds (IS) from the bottom third (IR)
is ,76%.
doi:10.1371/journal.pone.0010883.g002
Table 2. Correlation of IR-related metabolites with MFFM
based upon global biochemical screen results.*
Biochemical
Correlation
(r)M FFM p-value
a-hydroxybutyrate (a-HB) 20.45 1.40E-21
X-12063 20.36 7.92E-14
glycine 0.33 2.79E-11
urate 20.31 3.90E-10
X-12816 0.30 1.24E-09
a-ketobutyrate (a-KB) 20.28 1.54E-08
catechol-sulfate 0.27 6.16E-08
trigonelline (N-methylnicotinate) 0.26 7.86E-08
phosphate 0.24 8.18E-07
decanoylcarnitine 0.24 8.89E-07
X-11440 20.24 1.88E-06
3-methyl-2-oxovalerate 20.23 3.12E-06
3-methyl-2-oxobutyrate 20.23 3.24E-06
mannose 20.23 4.45E-06
octanoylcarnitine 0.23 5.11E-06
adrenate (22:4n6) 20.22 7.35E-06
cysteine 20.22 7.65E-06
creatine 20.22 9.05E-06
glycerate 0.22 1.07E-05
caprylate (8:0) 0.22 1.20E-05
quinate 0.22 1.48E-05
1-palmitoylglycerophosphoethanolamine 0.21 2.55E-05
isoleucine 20.21 2.81E-05
isovalerylcarnitine 20.21 3.13E-05
X-12844 20.21 3.32E-05
myo-inositol 0.20 3.70E-05
X-11421 0.20 3.91E-05
X-4055 20.20 5.02E-05
indolepropionate 0.20 6.29E-05
X-11537 0.19 9.33E-05
*Correlation coefficient with MFFM of the 30 top-ranked metabolites identified
by Random Forest are presented.
MFFM is expressed in mmol?min
21?kgFFM
21.
doi:10.1371/journal.pone.0010883.t002
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resistant (NGT-IR), with an age of 45 [11], median [interquartile
range], years and a BMI of 24.5 [4.7] kg?m
22. The 210 NGT
subjects who were more insulin sensitive (NGT-IS) (90 males, 120
females) were 44 [13] years of age and had a BMI of 23.5 [4.2]
kg?m
22. The 61 IFG subjects (42 males and 19 females) had an
age of 49 [12] years and a BMI of 27.3 [4.8] kg?m
22, while the 82
IGT subjects (37 males and 45 females) had an age of 45 [13] years
and a BMI of 27.9 [5.4] kg?m
22.
Shown in Figure 5 is a heat map of the global biochemical
profiling data set illustrating the statistical significance of changes
in the biochemicals in the various pair-wise group comparisons.
Four classes of metabolites that differentiate NGT-IS from
NGT-IR and/or NGT-IS from dysglycemia (IFG or IGT) are
highlighted. The organic acids a-ketobutyrate (a-KB), a-HB and
creatine readily distinguish NGT-IS subjects from both IGT and
IFG subjects, whereas a-HB and creatine serve as early indicators
of IR by readily distinguishing NGT-IS from NGT-IR subjects.
Similarly, lipid species such as acylcarnitines and lysoglyceropho-
spholipids also distinguish NGT-IS and NGT-IR subjects and
NGT-IS from IGT, with high statistical significance. In contrast,
fatty acids such as palmitate are later stage markers of impaired
glucose regulation, and only distinguish NGT-IS from IGT
subjects in the continuum of insulin resistance.
Targeted analysis of metabolites correlative of insulin
sensitivity
Consistent with previous reports [24], MFFM was significantly
lower in each of the IFG, IGT, and NGT-IR groups in
comparison with the NGT-IS group (p,0.0001 for each), as
illustrated in Figure 6A, while plasma a–HB concentrations
(Figure 6B), were the mirror image of MFFM. Using the targeted
assay, the measured levels of a–HB were significantly (p,0.0001)
higher in the NGT-IR, IFG and IGT groups as compared to the
NGT-IS group. Relatedly, by partition analysis, an a–HB
concentration of 5 mg/ml was found to best separate IR from IS
subjects. Furthermore, based upon multiple logistic regression
analysis, a–HB was significantly associated with IR independently
of center (collection site), sex, age, and BMI, with an odds ratio of
2.84 (C.I.: 2.02–4.00, p,0.0001) for each SD (=1.7 mg/ml) of
plasma a–HB.
Interestingly, RF analysis ranked a-HB as the most important
metabolite to classify NGT and IGT subjects, with a .70%
classification accuracy (data not shown). Consistent with these
observations, a–HB levels were significantly higher in IGT than
NGT subjects (p,0.0001), as shown in Figure 6B. To test
whether a-HB levels segregated with glucose dysregulation in
general, we grouped together IFG and IGT into one IGT
category, and by multiple logistic analysis a-HB was significantly
associated with IGT independently of center, sex, age, and BMI,
with an odds ratio of 2.51 (C.I.: 1.81–3.49, p,0.0001) for each SD
of plasma a–HB. Furthermore, both IR and IGT were each
independently associated with an a–HB concentration in the top
tertile of its plasma concentrations (i.e., 5.9 [1.7] mg/ml), with
respective odds ratios of 3.26 (C.I.: 1.83–5.81, p,0.0001) and 2.72
(C.I.: 1.51–4.92, p=0.0009) after adjustment for center, sex, age,
and BMI.
In addition to measuring a-HB by absolute quantitation,
targeted assays were also developed for candidate IR biomarkers
identified by RF and correlation analyses, with examples of
representative biochemical classes highlighted in Figure 5. The
results of these targeted assays are presented in Figure 6C–F. For
example, the lysophospholipid 1-linoleoylglycerophosphocholine
(Figure 6C) and long-chain acylcarnitines such as decanoylcarni-
tine (Figure 6D) decrease in concentration with increasing insulin
resistance and dysglycemia. Similarly, levels of the amino acid
glycine were observed to trend downward with IR (Figure 6E). In
contrast, similar to a-HB, the saturated fatty acid palmitate is
inversely correlated with insulin sensitivity (Figure 6F). Related to
this latter finding, a direct relationship between fasting plasma
a–HB concentrations and the mean free fatty acid (FFA) level
during the clamp (which averaged 30 [40] mmol/l) was observed;
this association was highly statistically significant (r
2=0.25,
p,0.0001) even after adjusting for center, sex, age, and BMI
(data not shown).
Figure 3. a-HB levels are higher in insulin resistant subjects in
both screening and targeted assays. A. Box plot of a-HB levels
measured in the non-targeted MS analysis (screening data). The X-axis
shows the groups and the Y-axis shows the relative normalized intensity
for a-HB median scaled to 1. B. Box plot of a-HB concentrations
measured using targeted isotopic dilution assays (targeted data). The
X-axis shows the groups and the Y-axis shows a-HB concentration in
mg/ml. In the box plots the top and bottom of the box represent the
75th and 25th percentile, respectively. The top and bottom bars
(‘‘whiskers’’) represent the entire spread of the data points for a-HB and
each group, excluding ‘‘extreme’’ points, which are indicated with black
squares. The black arrowheads indicate the mean value and the gray
arrowheads indicate the median value.
doi:10.1371/journal.pone.0010883.g003
Figure 4. Classification of subjects according to insulin
sensitivity and plasma glucose regulation. Schema showing the
partitioning of the 399 subjects into groups according to the results of
the oral glucose tolerance test (OGTT), fasting plasma glucose levels
(FPG) and M values derived from the clamp. NGT, normal glucose
tolerant; IGT, impaired glucose tolerant; NGT-IS, normal glucose tolerant
and insulin sensitive (MFFM.45 mmol?min
21?kgFFM
21); NGT-IR, normal
glucose tolerant and insulin resistant (MFFM#45 mmol?min
21?kgFFM
21);
IFG, normal glucose tolerant and impaired fasting glucose.
doi:10.1371/journal.pone.0010883.g004
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PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10883Summarized in Table 3 are representative targeted assay
results for top-ranking IR candidate markers, with regard to
their correlation to MFFM value and their fold changes in
concentration from the bottom tertile to the top two-thirds of
insulin sensitivity (green: decreased fold-change; red: increased
fold-change). Consistent with the screening data, a–HB is
highly correlated to the glucose disposal rate (r=0.45, p-value
1.15E-21).
Figure 6. Insulin-mediatedglucose disposal rates and representative metabolite levels in insulin resistant and dysglycemic
subjects. A. Box plots of insulin-mediated glucose disposal rates (MFFM, mmol?min
21?kgFFM
21); derived from the clamp in normoglycemic (NGT) and
dysglycemic (IGT, FPG) subjects. B. – F. Box plots of concentrations (mg/ml) of representative metabolites that change significantly with insulin
resistance and/or dysglycemia as measured by isotopic dilution assays in subjects with normal glucose tolerance that are insulin sensitive (NGT-IS)o r
insulin resistant (NGT-IS) and in dysglycemic subjects with impaired glucose tolerance (IGT) or impaired fasting plasma glucose levels (IFG). B. a-HB, C.
linoleoyl-GPC, D. decanoyl-carnitine, E. glycine, F. palmitate.
doi:10.1371/journal.pone.0010883.g006
Figure 5. Biochemicals showing significant change in subjects with IR and/or dysglycemia. A heat map graphical representation of
p-values obtained from statistical analysis of the global biochemical profiling of metabolites measured in plasma collected from NGT-IS, NGT-IR, IGT,
and IFG subjects. t-tests were performed to determine those metabolites that significantly increase or decrease in insulin resistant (IR) and
dysglycemic individuals (IGT, IFG). Highlighted from the main heat map include an organic acid, a-HB, the top-ranked biochemical for separating
NGT-IS from NGT-IR and NGT-IS from IGT; a cluster of long-chain fatty acids such as palmitate that are pronounced when comparing NGT-IS to IGT;
and acyl-carnitines and acylglycerophosphocholines that distinguish NGT-IR and IGT from NGT-IS. The color coding used, from white to dark blue,
indicate the most significant to least significant, respectively, with white, most statistically significant (p#1.0E-16); light blue (1.0E-16#p#0.001), royal
blue (0.001#p#0.01), and dark blue, not significant (p$0.1).
doi:10.1371/journal.pone.0010883.g005
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Using a non-targeted biochemical screening approach in a large
and well characterized cohort of nondiabetic subjects representing
a wide spectrum of insulin sensitivity, we identified a–hydroxybu-
tyrate (a–HB) as a biomarker segregating with clamp-derived IR
in subjects with normal glucose tolerance. Furthermore, a–HB
segregated with dysglycemia (IFG+IGT) independently of, and in
addition to, IR. Importantly, these associations were independent
of sex, age, and BMI. Thus, together with other biomarkers, a–HB
may provide a diagnostic tool to identify IR and/or IGT earlier
than currently used clinical tests.
a–HB is an organic acid derived from a-ketobutyrate (a–KB)
(Figure 7). a–KB is produced by amino acid catabolism (threonine
and methionine) and glutathione anabolism (cysteine formation
pathway) and is metabolized to propionyl-CoA and carbon dioxide
[25]. a–HB is formed as a by-product during the formation of a–KB
via a reaction catalyzed by lactate dehydrogenase (LDH) or a–
hydroxybutyrate dehydrogenase (a–HBDH) (Figure 7), an LDH
isoform present in the heart [26]. Accumulation of a–HB is
postulated to occur in vivo when either (a) the formation of a–KB
exceeds the rate of its catabolism, which leads to substrate
accumulation,or(b) there isproduct inhibition ofthe dehydrogenase
that catalyzes the conversion of a–KB to propionyl-CoA [25,27].
a–KB is also produced as a result of the conversion of cystathionine
to cysteine. Under conditions of increased oxidative stress, a higher
flux of cysteine into production of glutathione, the primary antioxidant
in cells, occurs from a shift in homocysteine production from
transmethylation of methionine to transsulfuration of homocysteine to
produce cystathionine [28] (Figure 7). In one report, a–HB was
associated with excess glutathione demand and disrupted mitochon-
drial energy metabolism and shown to derive from hepatic glutathione
stress [28], supporting the idea that elevated a–HB may be associated
with increased oxidative stress in the IR state.
a–HB may become elevated by at least two mechanisms: (1)
elevation of hepatic glutathione stress resulting in an increased
demand for glutathione production, and (2) elevation of the NADH/
NAD
+ ratio due to increased lipid oxidation. The first mechanism
likely contributes to increased a–HB formation by supplying more
a–KB substrate from increased cysteine anabolism (Figure 5).
Consistent with this interpretation, we observe statistically significant
elevation of both a-KB and cysteine with increasing insulin
resistance from the global screening data (Figures 2 & 5,
Table 2), similar to the trend observed with a-HB. In support of
the second proposed mechanism, increased lipid oxidation is a
metabolic feature of IR, and is indexed by the insulin-inhibited FFA
concentration [7,14]. Our finding of a positive association between
steady state FFA and plasma a–HB concentrations in the whole
cohortsupportsthe possibilitythatanincreased NADH/NAD
+ ratio
favors reduction of a–KB to a–HB (Figure 7).
Changes in other important IR-associated metabolites within
metabolic pathways leading to the formation of a-KB and a-HB
are highlighted in Figure 7. For example, reduced levels of
glycine (Figure 6E) and serine upstream of a-KB formation may
be consistent with increased gluconeogenesis which is observed
with IR in db-/db- mice [29]. Our interpretation that a redox
imbalance may contribute to elevated a-HB in the context of IR is
consistent with our finding that branched-chain alpha-keto acids,
such as 3-methyl-2-oxobutyrate, are elevated with IR (Table 3).
These increases may be due to the effect of the redox imbalance
on the directionality of the dehydrogenases that reduce/oxidize
these keto acids (Figure 7). In addition, a-HB has also been
observed to be elevated in T2D subjects and animal models of
T2D, as well as in severe lactic acidosis and ketoacidosis
[25,27,30,31,32,33,34]. Interestingly, in normal subjects and
T2D patients, it has been shown that restoration of the NADH/
NAD
+ redox balance by glutathione infusion therapy resulted in
improvement of insulin sensitivity and b-cell function in normal
subjects and in T2D patients [35].
In a recent study comparing the urinary profiles of 98
intermediary metabolites measured by targeted MS in 74 obese
and 67 lean individuals, Newgard et al. identified a metabolic
signature for the accumulation of branched-chain amino acids, the
glutamine/glutamate couple, several acylcarnitines, and some
Table 3. Correlation with MFFM and fold-change with IR of IR-related metabolites based upon targeted assays.*
Correlation coefficient (r) Fold change
Biochemical MFFM mmol?min
21?kgFFM
21 p-value Insulin sensitive/Insulin resistant (top 2/3/bottom tertile)
a-HB 20.45 1.15 e-21 1.38 q
1-linoleoyl-GPC 0.33 4.44 e-19 0.77 Q
glycine 0.32 2.64 e-11 0.85 Q
3-methyl-2-oxobutyrate 20.30 3.17 e-11 1.13 q
1-oleoyl-GPC 0.28 1.56 e-09 0.82 Q
creatine 20.26 1.29 e-07 1.30 q
decanoylcarnitine 20.25 4.24 e-07 0.73 Q
octanylcarnitine 20.20 4.40 e-05 0.79 Q
1-stearoyl-GPC 20.20 5.36 e-05 0.89 Q
adrenate (22:4n6) 20.19 9.51 e-05 1.19 q
stearate 20.18 0.000315 1.17 q
1-palmitoyl-GPC 20.17 0.0008423 0.90 Q
palmitate (16:0) 20.16 0.0013302 1.17 q
margarate 20.15 0.0023516 1.14 q
*The correlations with MFFM for the top 14 metabolites ranked by Random Forest are presented. Upward arrow (q) indicates metabolite concentration increased in
insulin resistant subjects; Downward arrow (Q) indicates metabolite concentration decreased in insulin resistant subjects.
doi:10.1371/journal.pone.0010883.t003
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component analysis [36]. These metabolites were also related to
insulin resistance (as determined by the HOMA index) and
interpreted as marking the metabolic consequences of excessive fat
and protein intake, with impairment of insulin signaling and
mitochondrial overload. It is noteworthy that in the non-targeted
metabolomics approach of the present study, lipid molecules,
branched-chain amino acids, and acylcarnitines were also featured
among the top 30 metabolites that RF analysis associated with the
M value (Figure 2). The current data narrow down the complex
interactions of amino acid and lipid metabolism [37] to highlight
the importance of a single marker, a–HB, which may reflect
oxidative burden in the context of IR.
With an unmet need for a practical clinical test that accurately
measures IR in individuals, identification of a–HB as a significant
biomarker for separating IR from IS subjects using a fasting
plasma sample could lead to development of such a diagnostic test.
a–HB in combination with other biochemical and clinical
parameters may also prove to be useful as a clinical indicator of
subclinical abnormalities of glucose metabolism.
Methods
Study subjects
RISC is a prospective, observational cohort study whose
rationale and methodology have been published previously [38].
In brief, participants were recruited at 19 centers in 13 countries in
Europe, according to following inclusion criteria: either sex, age
30–60 years, clinically healthy, stratified by sex and by age
according to 10-year age groups. Initial exclusion criteria were:
treatment for obesity, hypertension, lipid disorders or diabetes,
pregnancy, cardiovascular or chronic lung disease, weight change
of $5 kg in last month, cancer (in last 5 years), and renal failure.
Exclusion criteria after screening were: arterial blood pressure
$140/90 mmHg, fasting plasma glucose .7.0 mmol/l, 2-hour
plasma glucose (on a standard 75-g oral glucose tolerance test
[OGTT]) $11.0 mmol/l, total serum cholesterol $7.8 mmol/l,
serum triglycerides $4.6 mmol/l, and ECG abnormalities.
Baseline examinations began in June 2002 and were completed
in July 2005.
Of 1293 clamped RISC subjects, 194 males and 205 females –
median age 45 years and median body mass index (BMI) 25.0 kg m
22
(range 16.9–42.9) - were selected for non-targeted biochemical
profiling analysis. Based on the OGTT, 256 subjects had normal
glucose tolerance (NGT, i.e., fasting plasma glucose ,5.6 mmol/l
and 2-hour glucose ,7.8 mmol/l), 82 subjects had impaired glucose
tolerance (IGT, i.e., 2-hour glucose between 7.8–11.1 mmol/l), and
61 subjects had impaired fasting glycemia (IFG, i.e., fasting glucose
between 5.6–7.0 mmol/l).
EGIR-RISC study had undergone appropriate review by the
European Commission research program and its ethics committee.
Written consent was given by the patients for their information to
Figure 7. A Model of the biochemical relationship of a-HB biosynthesis and associated metabolic pathways with Insulin Resistance.
a-HB is produced from the conversion of a-KB in a reaction catalyzed by LDH that occurs when the NADH/NAD
+ ratio is elevated, as can occur from
higher lipid oxidation events. Metabolites that change significantly (screening and targeted data, p,0.01) are indicated by a box; arrows indicate the
direction of change. a-HB, alpha-hydroxybutyrate; a-KB, alpha-ketobutyrate; BCAA, branched chain amino acids; BCKDH, branched chain alpha keto
acid dehydrogenase; CBS, cystathionine-beta-synthase; CGL, cystathionine gamma-lyase; HBDH, a-hydroxybutyrate dehydrogenase; LDH, lactate
dehydrogenase; SAH, S-adenosyl-L-homocysteine; SAM, S-adenosyl Methionine. All compounds in boxes were measured using targeted assays, with
the exception of a-KB, cysteine and BCAAs.
doi:10.1371/journal.pone.0010883.g007
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aligned with the analysis described herein. The current retrospec-
tive analysis described herein did not require additional review by
said ethics committee due to prior approval of future biomedical
analyses when EGIR-RISC study was initiated.
Research protocol
Electrical bioimpedance (to measure fat-free mass), routine
clinical chemistry, OGTT, and HI clamp were performed as
described [38]. Insulin sensitivity was expressed as MFFM, in units
of mmol per min per kg of fat-free mass. Plasma free fatty acids
(FFA) were measured in the fasting state and at timed intervals
during the clamp; the values during the last 40 min of the clamp
were averaged to express insulin inhibition of circulating FFA.
Metabolomic analysis
Biochemical profiling was performed using multiple platform
(UHPLC and GC) mass spectrometry technology, as described
[18,19,39]. Briefly, a broad array of small molecule metabolites,
irrespective of class (e.g., amino acids, lipids, carbohydrates), was
examined to measure biochemical changes within plasma samples
collected after an overnight (10–12 hours) fast. The non-targeted
process used single sample extraction followed by protein
precipitation to recover a diverse range of molecules (e.g., polar,
hydrophobic).
Metabolite identification
Metabolites were identified by automated comparison and
spectra fitting to a chemical standard library of experimentally
derived spectra as previously described [18,19,39]. Identification
of known chemical entities was based on comparison with library
entries of purified authentic chemical standards. 485 biochemicals
were identified in this global biochemical profiling analysis, with
350 biochemicals measured in .50% of the entire data set. The
latter grouping of 350 biochemicals was used in all of the statistical
analyses.
Sample preparation
Upon receipt of fasted, baseline plasma samples from HI
clamps, aliquots were prepared and immediately frozen at 280uC
until time of analysis. At time of analysis, samples were thawed on
ice and 100 ml was extracted using an automated MicroLab
STARH system (Hamilton Company, Salt Lake City, UT). The
samples were extracted using a single extraction with 400 mlo f
methanol, containing the recovery standards: tridecanoic acid,
fluorophenylglycine, chlorophenylalanine and d6-cholesterol. The
solvent extraction step was performed by shaking for two minutes
using a Geno/Grinder 2000 (Glen Mills Inc., Clifton, NJ). After
extraction, the sample was centrifuged and supernatant removed
using the MicroLab STARH robotics system. The extract
supernatant was split into four equal aliquots: two for UHPLC/
MS, one for GC/MS and one reserve aliquot. Aliquots were
placed on a TurboVapH (Zymark) to remove solvent, and dried
under vacuum overnight. Samples were maintained at 4uC
throughout the extraction process. For UHPLC/MS analysis,
extract aliquots were reconstituted in either 0.1% formic acid for
positive ion UHPLC/MS, or 6.5 mM ammonium bicarbonate
pH 8.0 for negative ion UHPLC/MS. For GC/MS analysis,
aliquots were derivatized using equal parts N,O-bistrimethylsilyl-
trifluoroacetamide and a solvent mixture of acetonitrile:dichlor-
omethane:cyclohexane (5:4:1) with 5% triethylamine at 60uC for
1 hour. The derivatization mixture also contained a series of alkyl
benzenes for use as retention time markers.
GC/MS and UHPLC/MS/MS analysis
UHPLC/MS was carried out using a Waters Acquity UHPLC
(Waters Corporation, Milford, MA) coupled to an LTQ mass
spectrometer (Thermo Fisher Scientific Inc., Waltham, MA)
equipped with an electrospray ionization source. Two separate
UHPLC/MS injections were performed on each sample: one
optimized for positive ions and one for negative ions. The positive
ion analyses were performed first, followed by negative ion
analyses. The mobile phase for positive ion analysis consisted of
0.1% formic acid in H2O (solvent A) and 0.1% formic acid in
methanol (solvent B), while the mobile phase for negative ion
analysis consisted of 6.5 mM ammonium bicarbonate, pH 8.0
(solvent A) and 6.5 mM ammonium bicarbonate in 95% methanol
(solvent B). The acidic extracts were monitored for positive ions
and the basic extracts were monitored for negative ions in
independent injections using separate acid/base dedicated
2.16100 mm Waters BEH C18 1.7 mm particle columns heated
to 40uC. The extracts were loaded via a Waters Acquity
autosampler and gradient eluted (0% B to 98% B, with an 11
minute runtime) directly into the mass spectrometer at a flow rate
of 350 ml/min. The LTQ alternated between full scan mass
spectra (99–1000 m/z) and data dependent MS/MS scans, which
used dynamic exclusion.
The derivatized samples for GC/MS were analyzed on a
Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole
MS operated at unit mass resolving power. The GC column was
20 m60.18 mm with 0.18 mm film phase consisting of 5%
phenyldimethyl silicone. The temperature program started with
an initial oven temperature of 60uC and was ramped to 340uC,
with helium as the carrier gas. The MS was operated using
electron impact ionization with a 50–750 amu scan range and was
tuned and calibrated daily for mass resolution and mass accuracy.
Data normalization
Samples were analyzed over the course of two weeks. Each run
day was balanced for age, BMI, gender, OGTT, and insulin-
mediated total glucose disposal, MFFM). Within each day run,
samples were completely randomized to avoid group block effects.
The raw area counts for each metabolite in each sample were
normalized to correct for variation resulting from instrument inter-
day tuning differences. For each metabolite, the raw area counts
were divided by its median value for each run-day, therefore
setting the medians equal to 1 for each day’s run. This correctly
preserves all variation between samples, yet allows metabolites of
widely different raw peak areas to be compared directly on a
similar graphical scale. Missing values were assumed to result from
areas falling below limits of detection. For each metabolite, missing
values were imputed with its observed minimum after the
normalization step.
Data extraction and quality assurance
The data extraction of raw mass spectra data files yielded
information that was loaded into a relational database and
manipulated without resorting to BLOB manipulation. Once in
the database the information was examined and appropriate QC
limits were imposed. Peaks were identified using Metabolon’s
proprietary peak integration software, and component parts were
stored in a separate and specifically designed complex data
structure.
The median relative standard deviation (MRSD), a quality
assurance metric of quantification and measure of instrument
variability, was determined to be 8% for a panel of 30 internal
standards. Overall process variability (i.e., extraction, recovery,
resuspension, and instrument performance) for endogenous
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calculated to be 15% MRSD. These SD values reflected
acceptable levels of variability for overall process and instrumen-
tation of the analytical platform.
A variety of data curation procedures were carried out to ensure
that a high quality data set was made available for statistical
analysis and data interpretation. The QC and curation processes
were designed to ensure accurate and consistent identification of
true chemical entities, and to remove those representing system
artifacts, mis-assignments, and background noise. Metabolon data
analysts use proprietary visualization and interpretation software
to confirm the consistency of peak identification among the
various samples. Library matches for each compound were
checked for each sample and corrected if necessary. In addition
to rigorous identification, the quality of the automated Metabo-
lyzer integration (basis of quantitation) was verified for each
biochemical.
For QA/QC purposes a number of additional samples were
included with each day’s analysis. Briefly, a selection of internal
standards was added to every sample, immediately prior to
injection into the instrument. These compounds were carefully
chosen in order to not interfere with measurement of endogenous
compounds. These QC samples were primarily used to evaluate
process control for each study. Additionally, a small aliquot of each
experimental sample was pooled together to serve as a technical
replicate for duration of the run. This technical replicate sample
was injected throughout the platform run day and across all run
days, allowing variability in quantitation of all consistently
detected biochemicals in the experimental samples to be
monitored. With this monitoring, a metric on overall process
variability was assigned for the platform’s performance based on
quantitation of metabolites in actual experimental samples (see
results section).
Statistical Analysis
Data are given as median and [interquartile range]. Classifica-
tion and Regression Trees (CART), Random Forest (RF) [40],
multiple linear regression, correlation, and logistic regression
analyses were carried out on untransformed data, whereas log-
transformed data were used for t-testing. When data from NGT,
IGT, or IFG categories were used in comparisons for classification
by RF, the number of in-bag samples was set to 50% of smallest
sub-group to account for unbalanced samples sizes. For platform
screening data and targeted analytical data, we used 50,000 and
1,000 trees, respectively. Random forest analysis was performed
using the R-package ‘‘randomForest’’ [41]. Partition analysis
(JMP) was employed to find the metabolite value that best
separated the MFFM value into two groups. Multiple logistic
regression tested the independent association of metabolites with
lower tertile of insulin resistance; results are given as the odds ratio
and 95% confidence interval (C.I.). Statistical analyses were
performed using JMP (JMP, Version 8. SAS Institute Inc., Cary,
NC, 1989–2009), and ‘‘R’’ (http://cran.r-project.org/).
Targeted analytical methods
For absolute quantitation, metabolites were analyzed by isotope
dilution UHPLC-MS-MS (except for palmitoleic acid, palmitoyl-
lyso-PC, and oleoyl-lyso-PC). 50 ml of EDTA plasma samples were
spiked with internal standard solution and subsequently subjected
to protein precipitation by mixing with 250 ml of methanol.
Following centrifugation, aliquots of clear supernatant were
injected onto an UHPLC-MS-MS system, consisting of a Thermo
TSQ Quantum Ultra Mass Spectrometer and a Waters Acquity
UHPLC system equipped with a column manager module and
three different columns. Each sample was analyzed using three
different chromatographic systems to cover the various analytes.
a-Hydroxybutyric acid (a-HB), b-hydroxybutyric acid and 3-
methyl-2-oxo-butyric acid were eluted with a 0.01% formic acid in
water/acetonitrile-methanol (1:1) gradient on a Waters, Acquity
BEH C18 column (100 mm62.1 mm, 1.7 mm) at a mobile phase
flow rate of 0.4 ml/min at 40uC. Ionization was achieved by
negative HESI mode. Creatine, octanoyl carnitine, decanoyl
carnitine, glutamic acid, glycine, serine, threonine, palmitoyl-lyso-
PC, oleoyl-lyso-PC and linoleoyl-lyso-PC were eluted with a
0.01% formic acid in water/acetonitrile-water-ammonium for-
mate (700:300:2.7) gradient on a Thermo, BioBasic SCX column
(50 mm62.1 mm, 5 mm) at a mobile phase flow rate of 0.5 ml/
min at 40uC. Ionization was achieved by positive HESI mode.
Palmitic acid, palmitoleic acid, margaric acid, stearic acid, oleic
acid, and linoleic acid, were eluted isocratically with 15% 5 mM
ammonium bicarbonate in water and 85% acetonitrile-methanol
(1:1) on a Waters, Acquity BEH C18 column (100 mm62.1 mm,
1.7 mm) at a mobile phase flow rate of 0.4 ml/min at 40uC.
Ionization was achieved by negative HESI mode. Quantitation
was performed based on the area ratios of analyte and internal
standard peaks using a weighted linear least squares regression
analysis generated from fortified calibration standards in an
artificial matrix, prepared immediately prior to each run. The
following corresponding stable labeled compounds were used as
internal standards: a-HB-D3, b-HB-D3, 3-methyl-2-oxobutyric
acid-D7, palmitic acid-
13C16, margaric acid-D3, oleic acid-
13C18,
stearic acid-D3, linoleic acid-
13C18, linolenic acid-
13C18, (used for
palmitoleic acid), creatine-D3, octanoyl carnitine-D3, decanoyl
carnitine-D3, glutamic acid-D5, glycine-
13C2-
15N, serine-D3,
threonine-
13C4-
15N, tryptophan-D5, linoleoyl-lyso-PC-D9 (also
used for palmitoyl-lyso-PC and oleoyl-lyso-PC).
Quantitative determination of a-HB
For extraction, 0.0500 mL of human EDTA plasma was spiked
with 0.0200 mL a-HB-D3 internal standard solution (30.0 mg/mL)
and subjected to protein precipitation by vigorously mixing with
0.250 mL of methanol. Following centrifugation, the supernatant
was removed and 2.00 mL were injected onto a Waters Acquity/
Thermo Quantum Ultra LC-MS-MS system. Calibration range
included 0.500 to 20.0 mg/mL a-HB. Calibration standard
samples were prepared in 2% BSA or water. Chromatographic
conditions included the following: Waters, Acquity C 18 BEH
column, 1.7 micron 2.16100 mm; mobile phase A: 0.01% formic
acid in water; mobile phase B: acetonitrile-methanol (1:1); flow
rate: 0.400 mL/min; gradient: initial 99% phase A, 1.0 min 60%
phase A, linear, 1.4 min 60% phase A, 1.5 min 99% phase A; and
linear a-HB retention time was 1.22 min. Mass spectrometer
settings included selective reaction monitoring, negative ionization
mode; HESI source; Spray voltage: 22500 V; vaporizer temper-
ature: 300uC, Capillary temperature: 350uC; sheath/auxillary/
sweep gas: N2; collision gas: Ar, 0.5 mTorr; monitored transitions:
a-HB: m/z 103.1-.57.1, a-HB-D3: m/z 106.1-.59.1, collision
energy: 13 V, each.
Supporting Information
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